For the third time, biotech leaders from around the world are headed to San Diego to attend one of the largest gathering of industry professionals.  The event is expected to draw 16,000 attendees from 76 nations and have a $40.4 million impact on the local economy.

San Diego is the third largest biotech cluster in the world.  Biotechs in the region are leaders in genomics, drug discovery, personalized medicine, and stem cells.

Many of our clients are from San Diego, and we are proud the event is in our backyard.  We have worked closely with our clients and industry thought leaders on the following sessions, which explore: financing and deal trends; developing curative therapies for rare diseases; translating local breakthroughs to global medicines; modulating the immune system; regulations in regenerative medicine; and what’s next for the industry.

We hope to see you there!

Tuesday, June 20 at 10:45am – Room 8

State of the Industry: Biotechnology Financing and Deal Making Findings from the Ernst & Young Biotechnology Annual Report

  • Glen Giovannetti, Global Biotechnology Leader, EY (Moderator)
  • Carol Gallagher, PharmD, Partner, NEA
  • James Healy, General Partner, Sofinnova Ventures
  • John Mendlein, Ph.D., J.D., CEO and Director, aTyr Pharma
  • Adam Simpson, President and CEO, PvP Biologics

Mybio link:

Tuesday, June 20 at 1:45pm – Room 3

The Tale of the Many Therapeutic Roads Leading to Treatment of Rare Genetic Diseases

  • John Mendlein, Ph.D., CEO and Director, aTyr Pharma (Moderator)
  • Gerald Cox, M.D., Ph.D., Chief Medical Officer, Editas Medicine
  • Emil Kakkis, M.D., Ph.D., President and CEO, Ultragenyx Pharmaceutical

Mybio link:

Tuesday, June 20, 4:15pm – Room 8

Transforming Local Innovation into Global Innovation

  • Caroline Chen, Biotech Reporter, Bloomberg (Moderator)
  • Douglas Crawford, Ph.D., Managing Director, Mission Bay Capital and General Manager, QB3
  • Jay Lichter, Ph.D., Managing Director, Avalon Ventures
  • Damien McDevitt, VP BD Asia & Head US West Coast Hub, GlaxoSmithKline
  • Heather Steinman, Ph.D., MBA, VP BD & Executive Director, Technology Transfer, The Wistar Institute

Mybio link:

Wednesday, June 21 at 1:45pm – Room 6C

Modulating Our Immune System to Fight Disease

  • John Mendlein, Ph.D., CEO and Director, aTyr Pharma (Moderator)
  • Paul Biondi, SVP & Head of Business Development, Bristol-Myers Squibb
  • David King, Ph.D., SVP, Research, aTyr Pharma
  • Daniel Shoemaker, Ph.D., CSO, Fate Therapeutics

Mybio link:

Wednesday, June 21 at 4:15pm – Room 4

Restoring Health: Defining Global Regulatory Pathways that Support Regenerative Medicine

  • Noam Levey, National Health Reporter, LA Times (Moderator)
  • Barbara Freischem, Executive Director, European Biopharmaceutical Enterprises (EBE)
  • Keith Murphy, Chairman, Organovo
  • Celia Witten, Deputy Director, Center for Biologics Evaluation and Research, FDA

Mybio link:

Thursday, June 22 at 1:00pm – Room 6A, Upper Level

The Scientific American WorldVIEW Super Session: Wrapping Up and Looking Forward

  • Andrew Marshall, Chief Editor, Nature Biotechnology (Moderator)
  • Lawrence Bloch, MD, JD, President, Infinity Pharmaceuticals
  • Donald Jones, Chief Digital Officer, Scripps Translational Science Institute
  • John Mendlein, Ph.D., CEO and Director, aTyr Pharma
  • Susan Peschin, MHS, President and CEO, Alliance for Aging Research

Mybio link:

Pin It on Pinterest

Share This